HFMA responds to omega-3 pregnancy study

- Last updated on GMT

There are some good findings in the recent Adelaide omega-3 study on DHA in pregnancy , the Health Food Manufacturers’ Association has pointed out; but it is noteworthy that participants did not DHA throughout the whole 9 months but only in the latter stages of pregnancy.

The research investigated supplementation with 800 mg of dietary docosahexaenoic acid (DHA) per day on more than 2,000 pregnant women, concluding that increased levels do not result in lower levels of postpartum depression in mothers or improved cognitive and language development in their offspring. NutraIngredients.com’s coverage of the study is here. http://www.nutraingredients.com/Research/DHA-may-not-have-pregnancy-benefits-Study

However the HFMA points out that the positive findings within the study were: A major reduction in the number of children classed as ‘slow developers’; much fewer pre-term and low birth weight babies; improved general health with significant reductions in number of adverse health events, admissions to intensive care and even infant deaths.

“It should be noted that during this latest study the DHA was not consumed throughout the full term of the pregnancy as recommended, but only in the later stages of pregnancy,”​ HFMA said.

Related topics: Research, Suppliers

Related news

Show more

Follow us

Featured Events

View more

Products

View more

Webinars